Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
SHPH Shuttle Pharmaceuticals
- 0.700
- +0.009+1.26%
Close Feb 14 16:00 ET
- 0.707
- +0.007+0.99%
Post 20:01 ET
2.85MMarket Cap-0.16P/E (TTM)
0.708High0.680Low77.91KVolume0.680Open0.691Pre Close53.94KTurnover2.89%Turnover RatioLossP/E (Static)4.08MShares4.71052wk High-2.17P/B1.89MFloat Cap0.58052wk Low--Dividend TTM2.69MShs Float1010.080Historical High--Div YieldTTM4.05%Amplitude0.580Historical Low0.692Avg Price1Lot Size
Shuttle Pharmaceuticals News
Shuttle Pharmaceuticals | SCHEDULE 13G: Others
Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Shuttle Pharmaceuticals | 5/A: Annual statement of changes in beneficial ownership of securities (Amendment)-Director Schafer Joshua
Shuttle Pharmaceuticals | 5/A: Annual statement of changes in beneficial ownership of securities (Amendment)-Director Richards Steven M
Shuttle Pharmaceuticals | 5: Annual statement of changes in beneficial ownership of securities-Director Brown Milton
Shuttle Pharmaceuticals | 5: Annual statement of changes in beneficial ownership of securities-Director Richards Steven M
Shuttle Pharmaceuticals | 5: Annual statement of changes in beneficial ownership of securities-Director Schafer Joshua
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Holdings, Inc. Announces Change Order to Work Agreement with Theradex Systems for Phase 2 Study of Ropidoxuridine
Shuttle Pharmaceuticals | 424B3: Prospectus
Shuttle Pharmaceuticals | EFFECT: Others
Shuttle Pharmaceuticals | RW: Registration Withdrawal Request
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Announces Enrollment and Dosing of the First Patients in the Company's Phase II Clinical Trial of Ropidine for the Treatment of Glioblastoma Patients
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Provides Third Quarter 2024 Corporate Update
Shuttle Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Shuttle Pharmaceuticals | 424B4: Prospectus
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.